PMID- 16815345
OWN - NLM
STAT- MEDLINE
DCOM- 20060829
LR  - 20060703
IS  - 0037-1963 (Print)
IS  - 0037-1963 (Linking)
VI  - 43
IP  - 3 Suppl 5
DP  - 2006 Jul
TI  - Recent advances in the treatment of childhood immune thrombocytopenic purpura.
PG  - S11-7; discussion S18-9
AB  - Immune thrombocytopenic purpura (ITP), the most common bleeding disorder in 
      childhood, is a benign condition that typically resolves within 6 months 
      following diagnosis. While all would agree on drug treatment for children with 
      severe hemorrhage, management strategies of the minimally symptomatic child with 
      a very low platelet count can vary widely. The case for treatment is based 
      primarily on the risk for the uncommon complication of intracranial hemorrhage or 
      other serious bleeding. Numerous clinical studies clearly indicate that immune 
      globulins (intravenous immune globulin [IVIg] or anti-D) and corticosteroid 
      therapy (prednisone and megadose methylprednisolone) are effective in rapidly 
      raising platelet counts. However, physicians must ultimately decide whether to 
      use drug therapy for a patient with minimal symptoms and low platelet count or 
      adopt an "observation-only" approach. With this background, three fundamental 
      questions emerge when evaluating different clinical strategies and potential 
      outcomes: (1) Which children with ITP need treatment? (2) Which pharmacologic 
      agent best accomplishes the goals of drug treatment? (3) Can physicians better 
      predict the outcome of treatments?
FAU - Tarantino, Michael
AU  - Tarantino M
AD  - Comprehensive Bleeding Disorders Center and Department of Pediatrics, University 
      of Illinois College of Medicine at Peoria, Peoria, IL 61614, USA. 
      mdtara@hemophilia-ctr-peoria.com
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Semin Hematol
JT  - Seminars in hematology
JID - 0404514
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Immunoglobulins)
SB  - IM
MH  - Adrenal Cortex Hormones/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Humans
MH  - Immunoglobulins/adverse effects/*therapeutic use
MH  - Patient Selection
MH  - Platelet Count
MH  - Purpura, Thrombocytopenic, Idiopathic/diagnosis/*drug therapy/genetics
MH  - Treatment Outcome
RF  - 48
EDAT- 2006/07/04 09:00
MHDA- 2006/08/30 09:00
CRDT- 2006/07/04 09:00
PHST- 2006/07/04 09:00 [pubmed]
PHST- 2006/08/30 09:00 [medline]
PHST- 2006/07/04 09:00 [entrez]
AID - S0037-1963(06)00090-4 [pii]
AID - 10.1053/j.seminhematol.2006.04.008 [doi]
PST - ppublish
SO  - Semin Hematol. 2006 Jul;43(3 Suppl 5):S11-7; discussion S18-9. doi: 
      10.1053/j.seminhematol.2006.04.008.